Wire flash
FinanceAdaptive Biotechnologies Q2 2026 Earnings Call: Focus on MRD Testing Business
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Adaptive Biotechnologies held its Q2 2026 earnings conference call on July 29, 2026. The call was led by CEO Chad Robins, CFO Kyle Piskel, and other executives. They discussed the company's financial results for the second quarter, which were released earlier that day. The presentation included forward-looking statements and non-GAAP financial measures. Analysts from Piper Sandler, Guggenheim, BTIG, TD Cowen, JPMorgan, and Morgan Stanley participated in the Q&A session. The call covered the company's performance, strategic outlook, and market position in the biotechnology sector, particularly in minimal residual disease (MRD) testing.
Source report
Here is the rewritten news content as a clean, well-structured English Markdown document.
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call
Date: July 29, 2026 Time: 4:30 PM EDT
Company Participants
- Karina Calzadilla – Vice President of Investor Relations
- Chad Robins – Co-Founder, CEO & Chairman
- Kyle Piskel – VP, CFO & Principal Accounting Officer
- Susan Bobulsky – Chief Commercial Officer of MRD
Conference Call Participants
- David Westenberg – Piper Sandler & Co., Research Division
- Subhalaxmi Nambi – Guggenheim Securities, LLC, Research Division
- Mark Massaro – BTIG, LLC, Research Division
- Daniel Brennan – TD Cowen, Research Division
- Casey Woodring – JPMorgan Chase & Co, Research Division
- Kallum Titchmarsh – Morgan Stanley, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Karina Calzadilla, Head of Investor Relations. Please go ahead.
Karina Calzadilla
Vice President of Investor Relations
Thank you, Tonya, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies Second Quarter 2026 Earnings Conference Call.
Earlier today, we issued a press release reporting Adaptive financial results for the second quarter. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing the slide presentation that has been posted in the Investors section of our corporate website.
During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company. These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and listed in this presentation.
In addition, non-GAAP financial...
Source
All Articles on Seeking AlphaNeutral / independent
Part of this Story
Adaptive Biotechnologies Q2 2026 Earnings Call Transcript